A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®
View HTML
Toggle Summary Veracyte to Present at the UBS Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 3:00 p.m. Eastern Time .
View HTML
Toggle Summary Veracyte Announces First Quarter 2020 Financial Results
Total Testing and Product Revenue Increased 20% to $30.4 Million Genomic Testing Volume Grew 15% to 10,559 Executed Exclusive Licensing Agreement with Yale University To Advance Novel, Blood-Based Genomic IPF Monitoring Test on nCounter Platform Company Outlines COVID-19 Impact and Response
View HTML
Toggle Summary Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced that the company has launched “More About You,” a web-based campaign that is designed to educate patients about thyroid nodules, and empower them to both engage in conversations with their
View HTML
Toggle Summary Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Veracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for
View HTML
Toggle Summary CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Second paragraph, first sentence of release should include Dr. Jose Herazo-Maya , currently Director of Interstitial Lung Disease Program
View HTML
Toggle Summary Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
Expects first quarter revenue in the range of $30.5 million to $31.5 million Withdraws full-year 2020 guidance SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced preliminary, unaudited and unreviewed financial results for the first quarter
View HTML
Toggle Summary Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations
Company also announces that Alfred “Freddie” Bowie, Jr., Ph.D. has been named to Savoy Magazine’s “2020 Most Influential Black Executives in Corporate America” List SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has named Tracy
View HTML
Toggle Summary Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
Company launches expanded content to detect novel NTRK, ALK, RET and BRAF fusions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced results of a study that identified over 100 novel or rare NTRK, ALK, RET and BRAF
View HTML
Toggle Summary Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
Findings Based on Randomized Study of Danish Women with High-Risk, Early Breast Cancer Published in npj Breast Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. , (Nasdaq: VCYT) today announced the publication of a large, retrospective study in which the Danish Breast Cancer
View HTML